Placing

RNS Number : 2100T

Sareum Holdings PLC

24 March 2016

 

(AIM: SAR)

24 March 2016

Sareum Holdings plc

("Sareum" or "the Company")

Placing

The Company announces that it has raised approximately £1.1 million, before expenses, by way of a placing by Hybridan LLP and WH Ireland Limited of 157,785,715 new ordinary shares of 0.025p each in the capital of the Company (the "Placing Shares") at 0.7p per share.

The net proceeds of the placing will be used to progress the Company's drug development programmes as well as for working capital purposes.

Application will be made to the London Stock Exchange for the Placing Shares to be admitted to trading on AIM and it is expected that admission will become effective and trading will commence on 5 April 2016. The Placing Shares will rank pari passu with the existing ordinary shares of the Company.

Following the admission of the Placing Shares to trading on AIM, the Company will have a total of 2,645,223,988 shares  in issue. This figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in the Company under the FCA's Disclosure and Transparency Rules.

For further information, please contact:

Sareum Holdings PLC
Tim Mitchell	Tel: [phone]
WH Ireland Limited (Nominated Adviser and Co-Broker)
Chris Fielding / Nick Prowting	Tel: [phone]
Hybridan LLP (Co-Broker)
Claire Noyce / Niall Pearson	Tel: [phone]
The Communications Portfolio (Public Relations)
Ariane Comstive [e-mail]	Tel: [phone]

Notes for editors:

About Sareum Holdings plc

Sareum is a drug discovery and development company delivering targeted small molecule therapeutics, focusing on cancer and autoimmune disease, for licensing to pharmaceutical and biotechnology companies at the preclinical or early clinical trials stage.

Sareum operates an outsourced research model, working with collaborators (SRI International, the CRT Pioneer Fund and Hebei Medical University Biomedical Engineering Center) and a world-wide network of research providers. Its research pipeline includes a programme awaiting final approval to start clinical trials and another undergoing pre-clinical IND-enabling studies.

SKIL® (Sareum Kinase Inhibitor Library) is Sareum's drug discovery technology platform that has so far produced the Company's Aurora+FLT3, Aurora+ALK, VEGFR-3, FLT3 & TYK2 kinase cancer and autoimmune disease research programmes. SKIL® can also generate drug research programmes against other kinase targets.

Sareum Holdings plc is listed on the AIM market of the London Stock Exchange, trading under the symbol SAR. For further information, please visit www.sareum.co.uk

 

END

 

 

IOEBBGDXBUDBGLS